Relationship of ejection fraction and natriuretic peptide trajectories in heart failure with baseline reduced and mid-range ejection fraction.
Journal
American heart journal
ISSN: 1097-6744
Titre abrégé: Am Heart J
Pays: United States
ID NLM: 0370465
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
21
12
2020
accepted:
21
08
2021
pubmed:
29
8
2021
medline:
8
4
2022
entrez:
28
8
2021
Statut:
ppublish
Résumé
The prognostic importance of trajectories of neurohormones relative to left ventricular function over time in heart failure with reduced and mid-range EF (HFrEF and HFmrEF) is poorly defined. To evaluate left ventricular ejection fraction (LVEF) and B-type natriuretic peptide (BNP) trajectories in HFrEF and HFmrEF. Analyses of LVEF and BNP trajectories after incident HF admissions presenting with abnormal LV systolic function were performed using 3 methods: a Cox proportional hazards model with time-varying covariates, a dual longitudinal-survival model with shared random effects, and an unsupervised analysis to capture 3 discrete trajectories for each parameter. Among 1,158 patients (68.9 ± 13.0 years, 53.3% female), both time-varying LVEF measurements (P=.001) and log-transformed BNP measurements (p-values=2 × 10 Although LVEF trajectories have greater temporal variation, BNP trajectories provide additive prognostication and an even stronger association with survival times in heart failure patients with abnormal LV systolic function.
Sections du résumé
BACKGROUND
The prognostic importance of trajectories of neurohormones relative to left ventricular function over time in heart failure with reduced and mid-range EF (HFrEF and HFmrEF) is poorly defined.
OBJECTIVE
To evaluate left ventricular ejection fraction (LVEF) and B-type natriuretic peptide (BNP) trajectories in HFrEF and HFmrEF.
METHODS
Analyses of LVEF and BNP trajectories after incident HF admissions presenting with abnormal LV systolic function were performed using 3 methods: a Cox proportional hazards model with time-varying covariates, a dual longitudinal-survival model with shared random effects, and an unsupervised analysis to capture 3 discrete trajectories for each parameter.
RESULTS
Among 1,158 patients (68.9 ± 13.0 years, 53.3% female), both time-varying LVEF measurements (P=.001) and log-transformed BNP measurements (p-values=2 × 10
CONCLUSION
Although LVEF trajectories have greater temporal variation, BNP trajectories provide additive prognostication and an even stronger association with survival times in heart failure patients with abnormal LV systolic function.
Identifiants
pubmed: 34453882
pii: S0002-8703(21)00220-9
doi: 10.1016/j.ahj.2021.08.015
pmc: PMC8633031
mid: NIHMS1735717
pii:
doi:
Substances chimiques
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-10Subventions
Organisme : NHLBI NIH HHS
ID : R21 HL140445
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01 HL142848
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL127654
Pays : United States
Organisme : NHLBI NIH HHS
ID : R56 HL135556
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL147104
Pays : United States
Organisme : NHLBI NIH HHS
ID : R25 HL126146
Pays : United States
Organisme : NHLBI NIH HHS
ID : L30 HL148881
Pays : United States
Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
JACC Heart Fail. 2017 Nov;5(11):808-809
pubmed: 29096789
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Thromb Haemost. 2018 Jul;118(7):1296-1304
pubmed: 29723875
JACC Heart Fail. 2019 Apr;7(4):306-317
pubmed: 30852236
Scand Cardiovasc J. 2018 Aug;52(4):205-210
pubmed: 29656687
JAMA Cardiol. 2016 Aug 1;1(5):510-8
pubmed: 27434402
JACC Heart Fail. 2017 Nov;5(11):772-781
pubmed: 29096787
Ann Nutr Metab. 2014;65(2-3):205-10
pubmed: 25413659
JACC Heart Fail. 2016 Apr;4(4):237-48
pubmed: 26682794
Circ Heart Fail. 2012 Nov;5(6):720-6
pubmed: 22936826
Circ Res. 2018 Aug 17;123(5):614-629
pubmed: 30355136
JACC Heart Fail. 2017 Jul;5(7):507-517
pubmed: 28624483
J Am Coll Cardiol. 2019 Mar 26;73(11):1264-1272
pubmed: 30846338
Thromb Haemost. 2019 Dec;119(12):1901-1919
pubmed: 31499565
J Am Heart Assoc. 2017 Mar 30;6(4):
pubmed: 28360225
Circulation. 1996 Nov 1;94(9):2285-96
pubmed: 8901684
J Clin Oncol. 2010 Jun 1;28(16):2796-801
pubmed: 20439643
Stat Med. 2014 Nov 30;33(27):4715-33
pubmed: 25044061
JAMA Cardiol. 2020 Sep 1;5(9):1027-1035
pubmed: 32936274
Circulation. 2017 Feb 21;135(8):717-719
pubmed: 28223323
J Am Coll Cardiol. 2018 Aug 7;72(6):591-601
pubmed: 30071987
J Am Coll Cardiol. 2004 Jun 2;43(11):2022-7
pubmed: 15172407
J Stat Softw. 2016 Jul;71(3):
pubmed: 27616941
Stat Methods Med Res. 2018 Jul;27(7):2015-2023
pubmed: 29846144
Circulation. 2014 Jun 10;129(23):2380-7
pubmed: 24799515
Circulation. 2005 Dec 13;112(24):3738-44
pubmed: 16330684
J Card Fail. 2017 Aug;23(8):628-651
pubmed: 28461259
JAMA Cardiol. 2016 Aug 1;1(5):507-9
pubmed: 27434185
Curr Heart Fail Rep. 2019 Dec;16(6):274-284
pubmed: 31741231
Can J Cardiol. 2019 May;35(5):611-618
pubmed: 31030863
J Am Coll Cardiol. 2007 May 15;49(19):1943-50
pubmed: 17498579